nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-91A3F5C8·Framework v5.10·Pipeline v0.4·Evaluated 02 Nov 2026·OECD: 3.2 Clinical medicine·Subfield: Genetics·Basis: Full text·Type: Non-randomized or early-phase trial

Long-Term Integrated Safety and Efficacy of Garadacimab for Hereditary Angioedema Prophylaxis.

Craig et al.Craig, Guilarte, Li et al.·2026·Advances in therapy·10.1007/s12325-026-03628-x ↗

Primary claim

These integrated data, representing the longest garadacimab exposure reported to date, confirm the favorable long-term safety profile of garadacimab (exposure ≤ 5.5 years), and durable efficacy with sustained protection against HAE attacks (exposure ≤ 3.2 years).

Tentative · uncontrolled long-term extension evidence supports observation of persistence rather than confirmation of durable efficacy
In brief

Integrated garadacimab follow-up extends long-term safety evidence and documents sustained attack suppression, but uncontrolled extension data limit confirmation of durable efficacy.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Abstract

INTRODUCTION: Garadacimab (monoclonal antibody inhibiting activated factor XII [FXIIa]) is approved for long-term prophylaxis (LTP) against hereditary angioedema (HAE) attacks. Due to the novelty of FXIIa inhibition and the lifelong need for HAE LTP, long-term evaluation of garadacimab is important. Pooling data from multiple studies can provide valuable insights into treatment effects over longer durations. We report the integrated summary of safety (ISS) and efficacy (ISE) of garadacimab LTP across the HAE clinical development program.

METHODS: The ISS comprised data from phase 2 (13-week placebo-controlled period, 75/200/600 mg monthly or 400 mg every 2 weeks; ≥ 44-week open-label period, 200/600 mg monthly; NCT03712228), pivotal phase 3 (6 months; 200 mg monthly; NCT04656418), and ≥ 12-month phase 3 open-label extension (OLE) studies (200 mg monthly; NCT04739059). The ISE comprised data from phase 3 studies. Endpoints included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs) per protocol, and efficacy.

RESULTS: At data cutoff (June 15, 2024), median garadacimab exposure (ISS: any dose, n = 172) was 2.5 (range 0.2-5.5) years. Overall rates of TEAEs and garadacimab-related TEAEs were 2.8/patient-year and 0.2/patient-year, respectively. No deaths occurred; four TEAEs led to treatment discontinuation. Eleven patients experienced SAEs (0 garadacimab-related). No garadacimab-related AESIs were reported; one unrelated AESI was observed with garadacimab 600 mg (epistaxis; mild; resolved). The most common garadacimab-related TEAEs were mild/moderate injection-site reactions. In the ISE (median exposure 2.5 [range 0.3-3.2] years), the mean (95% confidence interval) monthly attack rate was 0.2 (0.1, 0.2) with garadacimab (n = 164), corresponding to a 94.9% (93.1, 96.7) reduction from run-in (3.5 [3.2, 3.9]).

CONCLUSION: These integrated data, representing the longest garadacimab exposure reported to date, confirm the favorable long-term safety profile of garadacimab (exposure ≤ 5.5 years), and durable efficacy with sustained protection against HAE attacks (exposure ≤ 3.2 years).

TRIAL REGISTRATION: ClinicalTrials.gov identifiers, NCT03712228, NCT04656418, NCT04739059.

Key Claims

Primary finding · Tentative

These integrated data, representing the longest garadacimab exposure reported to date, confirm the favorable long-term safety profile of garadacimab (exposure ≤ 5.5 years), and durable efficacy with sustained protection against HAE attacks (exposure ≤ 3.2 years).

uncontrolled long-term extension evidence supports observation of persistence rather than confirmation of durable efficacy

Abstract
Quote verified
Secondary · Supported

The mean (95% confidence interval) monthly attack rate was 0.2 (0.1, 0.2) with garadacimab (n = 164), corresponding to a 94.9% (93.1, 96.7) reduction from run-in (3.5 [3.2, 3.9]).

descriptive treatment-versus-run-in comparison documents a large reduction without a concurrent long-term control

Abstract, Results, Efficacy Outcomes
Quote verified
Secondary · Supported

98.2% of patients who received garadacimab (n = 161/164) had a ≥ 50% reduction in attack rate and 84.8% (n = 139/164) had a ≥ 90% reduction

reported responder counts support the descriptive proportions within a pooled extension and run-in comparison

Results, Efficacy Outcomes
Quote verified
Secondary · Tentative

These data confirm a favorable safety profile with low rates of ISRs and no abnormal bleeding or thromboembolic events.

descriptive safety follow-up includes one mild unrelated bleeding event omitted by the unqualified conclusion

Conclusion
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#methodological rigour

Safety reporting connects events with exposure

Tables 2–3 report adverse events with patient denominators, exposure-adjusted rates, severity, and relatedness. Serious events and all four adverse-event-related discontinuations are described.

↳ Results, Safety Outcomes, Tables 2–3

#contribution

Continuous tracking extends accumulated safety observation

Unique patient identifiers connect follow-up across three studies, extending maximum safety exposure to 5.5 years. This adds observation relevant to a treatment intended for lifelong prophylaxis.

↳ Methods, Study Design; Results, Baseline Characteristics and Exposure

#reporting

Efficacy estimates remain numerically traceable throughout

The report gives attack-rate confidence intervals and explicit responder numerators and denominators. It also explains why one placebo participant was excluded from the efficacy analysis.

↳ Results, Baseline Characteristics and Exposure; Efficacy Outcomes

Limitations

#methodological rigour

Long-term confirmation exceeds the comparative design

Later efficacy observations principally derive from open-label extension and run-in comparisons rather than a concurrent long-term control. The randomized parent phase does not establish comparative durability throughout subsequent follow-up.

↳ Methods, Study Design and Analysis; Results, Efficacy Outcomes; Conclusion

#positioning

Durability limitations remain outside the interpretation

The Discussion addresses statistical power and sex-specific analysis but does not explain how selection, attrition, or the missing long-term comparator constrain its durability conclusion.

↳ Discussion, durability and limitations paragraphs

#reporting

No-bleeding conclusion omits a necessary qualifier

The Conclusion states that no abnormal bleeding occurred, although Results reports one mild, unrelated epistaxis AESI. The defensible statement is that no garadacimab-related abnormal bleeding was observed.

↳ Results, Safety Outcomes; Conclusion

Does this match your read? Add your assessment ↓

Nabu Commentary

The integrated analysis extends garadacimab safety observation through continuous cross-study tracking and reports adverse events with denominators, severity, relatedness, and exposure-adjusted rates. Its contribution is primarily an extension and consolidation of the existing clinical program. Large attack-rate reductions are documented, but the later open-label observations and run-in comparisons cannot confirm comparative long-term durability. The Discussion does not carry comparator and selection limitations into that interpretation, and the Conclusion's no-bleeding statement requires qualification for the reported unrelated epistaxis event.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.0±0.1

Contribution
3.3

Pooling three studies extends accumulated safety exposure and continuous patient follow-up for a therapy intended for lifelong prophylaxis. The advance remains incremental because the findings principally consolidate the existing clinical program rather than establish a new controlled long-term comparison.

Introduction, final paragraph; Methods, Study Design; Discussion, strengths paragraph
Methodological Rigour
2.8

Denominator-based and exposure-adjusted safety reporting supports descriptive long-term surveillance. Confirmatory durability claims exceed the uncontrolled extension and run-in design, and promotion of the post hoc pooled analysis is priced before the binding methodological ceiling.

Methods, Analysis and Statistical Methods; Results, Tables 2–3 and Efficacy Outcomes; Conclusion
Reporting
3.3

The organization, exposure periods, numerical estimates, and safety tables make the findings traceable. Central confirmatory wording and the unqualified no-bleeding statement communicate greater certainty than the reported evidence supports.

Abstract; Results, Tables 2–3; Conclusion
Positioning
2.8

The paper connects FXIIa inhibition with guideline goals, congenital factor XII deficiency, and the parent studies. Its limitations discussion does not adequately contextualize the lack of a concurrent long-term comparator or possible selection and attrition when interpreting durability.

Introduction; Discussion, durability and limitations paragraphs

Lower confidence on Contribution, Positioning — domain match limited.

Reliability

Caveats4 of 4 checks


Results checkNoted
  • These data confirm a favorable safety profile with low rates of ISRs and no abnormal bleeding or thromboembolic events: "no abnormal bleeding or thromboembolic events" (Conclusion) vs "a patient receiving garadacimab 600 mg experienced one episode of mild, unexplained epistaxis" (Results, Safety outcomes). One abnormal-bleeding AESI was reported, so the conclusion requires the treatment-related qualifier used elsewhere in the safety results. → Conclusion holds
Reporting and transparencyClean

Ethics approval, consent, and registration of the parent trials are declared, and the pooled analysis is identified as post hoc. Unavailable supporting materials and unstated availability disclosures do not establish suspicious conduct.

Ethics approval: declared · Preregistration: declared

Reference IntegrityClean

30 references in manuscript 22 of 22 checkable references found in an index 8 are books, websites or datasets — counted, but not index-checkable

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 02 Nov 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Skin · Other skin and subcutaneous diseases
Type of advanceEmpirical
Route to useSuggested
AdvanceConsolidates
BeneficiariesCatch-all cause
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessValidated
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

Pooled data across three clinical studies at multiple international sites with up to 5.5 years of exposure confirm long-term safety and efficacy beyond the individual trials.

From the paper
“garadacimab LTP has the potential to help patients with HAE achieve the guideline goal of complete disease control”

The paper names a real-world use of the findings, sustained long-term prophylaxis toward complete disease control, but does not specify who would act on them.

Pathway

Allergists and immunologists treating hereditary angioedema patients would use these long-term safety and efficacy data to sustain garadacimab prophylaxis decisions.

Barrier

The evidence comes from unpooled-power open-label extension periods and placebo-controlled trials, so real-world post-marketing surveillance data is still needed.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks

    Riedl, Farkas, Aygören-Pürsün, et al. · 2024 · Clinical medicine

    Primary claim

    Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo.

    Well-supported
    Evidence Score
    4.2±0.2
    Reliability
    No concerns
  2. Efficacy and Safety of Donidalorsen for Hereditary Angioedema

    Riedl, Tachdjian, Lumry, et al. · 2024 · Clinical medicine

    Primary claim

    Donidalorsen at a dose of 80 mg administered subcutaneously every 4 or 8 weeks significantly reduced the hereditary angioedema attack rate

    Supported
    Evidence Score
    4.0±0.1
    Reliability
    Caveats
  3. CRISPR-Based Therapy for Hereditary Angioedema

    Cohn, Gurugama, Magerl, et al. · 2024 · Clinical medicine

    Primary claim

    NTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema.

    Tentative
    Evidence Score
    3.6±0.1
    Reliability
    Caveats

How the rubric works →